16:20 EDT OptiNose trading resumes
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPTN:
- OptiNose Inc: FDA Approval and Future Pediatric Study for XHANCE
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
- Optinose initiated with a Buy at H.C. Wainwright
- Optinose reports Q4 EPS (9c), consensus (9c)
- Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights